论文部分内容阅读
Background: Early initiation of Lenvatinib in radioactive-iodine-refractory differentiated thyroid cancer (RR-DTC) patients improves prognosis,but initiating Lenvatinib too early burdens patients unnecessarily with cost and side effects.